Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTNYSE:AMTNYSE:ASG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$4.42-7.2%$5.70$2.90▼$11.16$357.45M0.473.34 million shs4.95 million shsAMTAmerican Tower$218.72-1.4%$216.46$172.51▼$243.56$102.31B0.822.50 million shs766,980 shsASGLiberty All-Star Growth Fund$5.47-1.0%$5.23$4.01▼$6.08N/A1.24264,693 shs158,292 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune0.00%+36.00%-15.30%+19.60%-28.10%AMTAmerican Tower0.00%+1.69%+4.32%+4.03%+13.34%ASGLiberty All-Star Growth Fund0.00%+1.09%+2.62%+24.72%+1.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.2136 of 5 stars3.51.00.00.02.41.70.6AMTAmerican Tower3.9053 of 5 stars2.63.01.73.13.61.70.0ASGLiberty All-Star Growth FundN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 3.00Buy$19.00330.35% UpsideAMTAmerican Tower 3.11Buy$240.259.85% UpsideASGLiberty All-Star Growth Fund 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ASG, ADR, AMT, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform6/27/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.005/19/2025AMTAmerican TowerBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$255.005/1/2025AMTAmerican TowerRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$240.00 ➝ $250.004/30/2025AMTAmerican TowerWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$230.00 ➝ $240.004/30/2025AMTAmerican TowerScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$234.00 ➝ $248.004/30/2025AMTAmerican TowerJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$248.00 ➝ $260.004/30/2025AMTAmerican TowerRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$231.00 ➝ $251.004/30/2025AMTAmerican TowerUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$245.00 ➝ $250.004/22/2025AMTAmerican TowerScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform4/22/2025AMTAmerican TowerScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$220.00 ➝ $234.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K17,905.03N/AN/A$1.74 per share2.54AMTAmerican Tower$10.13B10.11$11.42 per share19.15$20.64 per share10.60ASGLiberty All-Star Growth FundN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$95.06M-$1.26N/AN/AN/A-451,200.00%-65.44%-58.43%8/6/2025 (Estimated)AMTAmerican Tower$2.26B$3.8956.1821.871.6517.34%30.20%4.82%7/29/2025 (Estimated)ASGLiberty All-Star Growth FundN/AN/A0.00∞N/AN/AN/AN/AN/ALatest ASG, ADR, AMT, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2025Q2 2025AMTAmerican Tower$2.59N/AN/AN/A$2.58 billionN/A5/13/2025Q1 2025ALTAltimmune-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million4/29/2025Q1 2025AMTAmerican Tower$2.41$2.75+$0.34$2.75$2.54 billion$2.56 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AAMTAmerican Tower$6.803.11%N/A174.81%1 YearsASGLiberty All-Star Growth Fund$0.468.42%N/AN/AN/ALatest ASG, ADR, AMT, and ALT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/15/2025AMTAmerican Towerquarterly$1.703.21%6/13/20256/13/20257/11/20254/14/2025ASGLiberty All-Star Growth Fundquarterly$0.109.6%4/17/20254/17/20256/2/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A15.8515.85AMTAmerican Tower3.430.810.81ASGLiberty All-Star Growth FundN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%AMTAmerican Tower92.69%ASGLiberty All-Star Growth Fund21.62%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%AMTAmerican Tower0.18%ASGLiberty All-Star Growth Fund0.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5081.11 million77.78 millionOptionableAMTAmerican Tower4,691468.14 million467.30 millionOptionableASGLiberty All-Star Growth FundN/AN/AN/ANot OptionableASG, ADR, AMT, and ALT HeadlinesRecent News About These CompaniesLiberty All-Star® Growth Fund, Inc. Declares Distribution, Payable on September 2, 20251 hour ago | marketscreener.comMWhy We Love to Buy “Freshly Cut” Dividends (3 Yielding Up to 13.6%)...July 6 at 10:05 PM | marketbeat.comThese 3 Big Dividends Just Got Cut. They're Safer Than EverJune 24, 2025 | forbes.comLiberty All-Star Growth Fund (NYSE:ASG) Short Interest UpdateJune 18, 2025 | marketbeat.comASG: Exchanging Growth For IncomeJune 18, 2025 | seekingalpha.comLiberty All-Star® Growth Fund, Inc. April 2025 Monthly UpdateMay 15, 2025 | businesswire.comLiberty All Star Growth Stock Price, Quotes and Forecasts | NYSE:ASG | BenzingaApril 20, 2025 | benzinga.comLiberty All-Star® Growth Fund, Inc. March 2025 Monthly UpdateApril 15, 2025 | prnewswire.comLiberty All-Star® Growth Fund, Inc. Declares DistributionApril 7, 2025 | prnewswire.comLiberty All Star Growth Closed FundApril 6, 2025 | uk.investing.comASG: Price Drop Provides An Opportunity To Accumulate (Rating Upgrade)March 30, 2025 | seekingalpha.comLiberty All-Star® Growth Fund, Inc. February 2025 Monthly UpdateMarch 14, 2025 | prnewswire.comLiberty All-Star® Growth Fund, Inc. January 2025 Monthly UpdateFebruary 14, 2025 | prnewswire.com(ASG) Pivots Trading Plans and Risk ControlsJanuary 30, 2025 | news.stocktradersdaily.comNLiberty All-Star® Growth Fund, Inc. December 2024 Monthly UpdateJanuary 14, 2025 | prnewswire.comLiberty All-Star Growth declares $0.12 dividendJanuary 14, 2025 | msn.comLIBERTY ALL-STAR® Growth Fund, Inc. Declares DistributionJanuary 13, 2025 | prnewswire.comASG: Discounted Valuation But Choppy PerformanceJanuary 12, 2025 | seekingalpha.comLiberty All-Star® Growth Fund, Inc. November 2024 Monthly UpdateDecember 13, 2024 | prnewswire.comLiberty All-Star GrowthDecember 11, 2024 | morningstar.comMWhen the Price of (ASG) Talks, People ListenDecember 8, 2024 | news.stocktradersdaily.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendInsiders Chase Income and Stability in American Tower—Here’s WhyBy Gabriel Osorio-Mazilli | June 25, 2025View Insiders Chase Income and Stability in American Tower—Here’s WhyASG, ADR, AMT, and ALT Company DescriptionsAltimmune NASDAQ:ALT$4.42 -0.35 (-7.25%) As of 02:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.American Tower NYSE:AMT$218.72 -3.04 (-1.37%) As of 02:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.American Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of over 224,000 communications sites and a highly interconnected footprint of U.S. data center facilities.Liberty All-Star Growth Fund NYSE:ASG$5.46 -0.06 (-1.00%) As of 02:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Liberty All-Star Growth Fund, Inc. is a closed-ended equity mutual fund launched and managed by ALPS Advisers, Inc. It is co-managed by Weatherbie Capital, LLC, Congress Asset Management Company, and Sustainable Growth Advisers, LP. The fund invests in the public equity markets of the United States. It seeks to invest in stocks of companies operating across diversified sectors. The fund primarily invests in growth stocks of companies across all market capitalizations. It employs fundamental analysis with a bottom-up stock picking approach to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Composite Index, Russell 3000 Growth Index, and the S&P 500 Index. It conducts in-house research to make its investments. The fund was previously known as Charles Allmon Trust, Inc. Liberty All-Star Growth Fund, Inc. was formed on March 14, 1986 and is domiciled in the United States. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Warehouse Wars: Can BJ’s Take Advantage of Costco’s Weakness? Why Freeport-McMoRan Is The Copper King in a Tight Market Correction Equals Opportunity in Domino’s Pizza Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
